medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2013, Number s1

Arch Neurocien 2013; 18 (s1)

A prospective proteomic-based study for identifying potential biomarkers for the diagnosis of damage in focal cerebral ischemia induced in a rat model

Sánchez-Hernández H, Vite-Bazan CO, Heras-Romero Y, Cázares Raga FE, Cortés Martínez l, Ortiz PA, Hernández-Hernández FC

Language: Spanish
References: 22
Page: 27-32
PDF size: 965.61 Kb.


ABSTRACT

Cerebral vascular diseases are the third cause of death in Mexico and around the world; including focal cerebral ischemia (FCI) that leads to reduced blood supply in a specific zone of the brain, diminishing the glucose and oxygen. In early FCI stages there are molecular changes not well described in the cells of the affected and surrounding regions; these changes could be detected and used as biomarkers in easily accessed corporal fluids as blood serum (BS), in order to define biomarkers useful for disease advance diagnostic. Objective: analyze protein profile of rat sanguineous serum after 1h of FCI with or without 24h of sanguineous reperfusion (rpf), in order to identify possible early FCI biomarkers. Material and methods: cerebral focal ischemia was experimentally induced in brain rat, BS was obtained and serum albumin and immunoglobulin were depleted. Protein profile of serum samples were obtained by two dimensional gel electrophoresis, the images were analyzed using ImageMaster 2D Platinum software allowing to identify proteins present differentially in FCI. Results: under FCI and rpf, we observed up regulation of five proteins and down regulation of three proteins. To analyze their role as biomarkers in FCI, those proteins will be identified by mass spectrometry. Discussion and conclusion: protein analysis of corporal liquids is useful to find biomarkers to diagnostic and disease control. Proteins changes expression and localization with FCI aggrieving or dismissing injury, and BS could contain diagnostic markers to FCI useful to identify early changes in neurons and glial cells.


REFERENCES

  1. Traystman R. Animal models of focal and global cerebral ischemia. Ilar 2003; 44(2):85 95.

  2. Organización Mundial de la Salud (OMS). Datos y estadísticas; porcentajes de muertes al año alrededor del mundo 2004. [en línea].

  3. Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol Biochem Behav 2007; 87(1):179 97.

  4. Markus HS. Unravelling the Genetics of Ischaemic Stroke. PLoS Med. 2010;7(3):e1000225.

  5. Wu HW, Li HF, Wu XY, Zhao J, Guo J. Reactive oxygen species mediate ERK activation through different Raf 1 dependent signaling pathways following cerebral ischemia. Neurosci Lett 2008;20; 432(2):83 7.

  6. Mischak H, Apweller R. Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics CLin Appl 2007;1:148 56.

  7. Lescuyer P, Hochstrasser D, Rabilloud T. How shall we use the proteomics toolbox for biomarker discovery. J Proteome Analysis 2007;6:3371 6.

  8. Drake R, Cazares L, Semmes J. Mining the low molecular weight proteome of blood. Proteomics Clin. Appl 2007;1:758 68.

  9. Montaner J. Tratamiento del ictus isquémico. Valencia, 558, ático 2. España: Marge. 2009.

  10. Zea Longa E. Reversible middle cerebral artery occlusion without craniectomy in rats. Am Heal Associat 1989;20:84 91.

  11. Ortiz Plata Alma, Nader Kawachi Juan, Guevara Jorge, Sandoval Carlos,Rembao Daniel, Jorge Guevara, et al. EGP 314 is expressed differentially in three brain zones at an early time in an experimentally induced ischemia rat model. Mol Brain 2005; Res 137:55 62.

  12. Vivanco F, López L, Tuñon J, Egido J. Proteómica y enfermedad cardiovascular. Rev Esp Cardiol 2003; 56(3):289 302.

  13. Allard L, Burkhard PR, Lescuyer P, Burgess JA, Walter N, Hochstrasser DF. PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin Chem 2005 nov; 51(11):2043 51.

  14. Ionova VG, Lantsova VB, Maximova M Ya, Tkatch EN, Ziganshin RH. Proteomic studies of blood plasma of patients with the ischemic strocke in its most acute period. Series on Biomechanics 2012; 27(1 2):59 63.

  15. Vivanco F, Mas S, Darde VM, De la Cuesta F, Álvarez Llamas G, G. Vascular proteomics. Proteomics Clin Appl 2007;1:1102 22.

  16. Herrera M, Gállego J, Muñoz R, Aymerich N, Zandio B. [Reperfusion in acute ischaemic stroke: present and future]. An Sist Sanit Navar. 2008; 31 Suppl 1:31 46. Spanish.

  17. Sironi L, Tremoli E, Miller I, Guerrini U, Calvio AM, Eberini I, et al. Acute Phase Proteins Before Cerebral Ischemia in Stroke Prone rats: Identification by Proteomics. Stroke 2001; 32:753 60.

  18. Sánchez HH, Análisis proteómico de las modificaciones producidas por la isquemia cerebral focal en un modelo de rata. México, D.F. Centro de Investigación y de estudios Avanzados del IPN, 2010.

  19. Jung CS, Lange B, Zimmermann M, Seifert V. CFS and serum biomarkers focusing on cerebral vasospasm and ischemia after subarachnoid hemorrhage. Stroke research and treatment. 2013;vol. 2013:7.

  20. Peña Tapia P. Oclusión endovascular permamente de la arteria cerebral media en ratas wistar: descripción del abordaje a través de la arteria carótida interna. Rev Neurol 2004;39 (11):1011 6.

  21. Kotan D, Deniz O,Aygul R, Yildirim A. Acute cerebral ischaemia: relationship between serum and cerebrospinal fluid orexin A concentration and infarct volumen. Inter Med Res 2013; 41(2):404 9.

  22. Gruden G, Barutta F, Catto I, Bosco G, Caprioli MG, Pinach S, et al. Serum levels og heat shock protein 27 in patients with acute ischemic stroke. Cell Stress Chaperones 2013;18:531 3.




2020     |     www.medigraphic.com